Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Digital genomic quantification of tumor-infiltrating lymphocytes.

Robins HS, Ericson NG, Guenthoer J, O'Briant KC, Tewari M, Drescher CW, Bielas JH.

Sci Transl Med. 2013 Dec 4;5(214):214ra169. doi: 10.1126/scitranslmed.3007247.

2.

An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription.

Knouf EC, Garg K, Arroyo JD, Correa Y, Sarkar D, Parkin RK, Wurz K, O'Briant KC, Godwin AK, Urban ND, Ruzzo WL, Gentleman R, Drescher CW, Swisher EM, Tewari M.

Nucleic Acids Res. 2012 Jan;40(2):499-510. doi: 10.1093/nar/gkr731. Epub 2011 Sep 14.

3.

Potential role of HE4 in multimodal screening for epithelial ovarian cancer.

Urban N, Thorpe JD, Bergan LA, Forrest RM, Kampani AV, Scholler N, O'Briant KC, Anderson GL, Cramer DW, Berg CD, McIntosh MW, Hartge P, Drescher CW.

J Natl Cancer Inst. 2011 Nov 2;103(21):1630-4. doi: 10.1093/jnci/djr359. Epub 2011 Sep 14.

4.

Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition.

Bendoraite A, Knouf EC, Garg KS, Parkin RK, Kroh EM, O'Briant KC, Ventura AP, Godwin AK, Karlan BY, Drescher CW, Urban N, Knudsen BS, Tewari M.

Gynecol Oncol. 2010 Jan;116(1):117-25. doi: 10.1016/j.ygyno.2009.08.009. Epub 2009 Oct 24.

5.

Circulating microRNAs as stable blood-based markers for cancer detection.

Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M.

Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8. doi: 10.1073/pnas.0804549105. Epub 2008 Jul 28.

6.

Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains.

Faça VM, Ventura AP, Fitzgibbon MP, Pereira-Faça SR, Pitteri SJ, Green AE, Ireton RC, Zhang Q, Wang H, O'Briant KC, Drescher CW, Schummer M, McIntosh MW, Knudsen BS, Hanash SM.

PLoS One. 2008 Jun 18;3(6):e2425. doi: 10.1371/journal.pone.0002425.

7.

Bead-based ELISA for validation of ovarian cancer early detection markers.

Scholler N, Crawford M, Sato A, Drescher CW, O'Briant KC, Kiviat N, Anderson GL, Urban N.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2117-24.

8.

Evidence of a founder effect and refinement of the hereditary neuralgic amyotrophy (HNA) locus on 17q25 in American families.

Watts GD, O'Briant KC, Chance PF.

Hum Genet. 2002 Feb;110(2):166-72. Epub 2001 Dec 18.

PMID:
11935323
9.

A rare polyadenylation signal mutation of the FOXP3 gene (AAUAAA-->AAUGAA) leads to the IPEX syndrome.

Bennett CL, Brunkow ME, Ramsdell F, O'Briant KC, Zhu Q, Fuleihan RL, Shigeoka AO, Ochs HD, Chance PF.

Immunogenetics. 2001 Aug;53(6):435-9.

PMID:
11685453
10.

Rater agreement and utility of the mutagen-induced chromosome damage assay.

McIntyre LM, O'Briant KC, McBride CM, Bepler G.

Anticancer Res. 2001 Jan-Feb;21(1B):605-9.

PMID:
11299813
11.

Evidence for genetic heterogeneity in hereditary neuralgic amyotrophy.

Watts GD, O'Briant KC, Borreson TE, Windebank AJ, Chance PF.

Neurology. 2001 Mar 13;56(5):675-8.

PMID:
11245726
12.

SSA/RO52gene and expressed sequence tags in an 85 kb region of chromosome segment 11p15.5.

Kim YC, Cao Y, Pitterle DM, O'Briant KC, Bepler G.

Int J Cancer. 2000 Jul 1;87(1):61-7.

13.

Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1).

Pitterle DM, Kim YC, Jolicoeur EM, Cao Y, O'Briant KC, Bepler G.

Mamm Genome. 1999 Sep;10(9):916-22.

PMID:
10441745
14.

Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.

Boyer CM, Pusztai L, Wiener JR, Xu FJ, Dean GS, Bast BS, O'Briant KC, Greenwald M, DeSombre KA, Bast RC Jr.

Int J Cancer. 1999 Aug 12;82(4):525-31.

15.

A 1.4-Mb high-resolution physical map and contig of chromosome segment 11p15.5 and genes in the LOH11A metastasis suppressor region.

Bepler G, O'briant KC, Kim YC, Schreiber G, Pitterle DM.

Genomics. 1999 Jan 15;55(2):164-75.

PMID:
9933563
16.
17.

Association of chromosome 11 locus D11S12 with histology, stage, and metastases in lung cancer.

Bepler G, Fong KM, Johnson BE, O'Briant KC, Daly LA, Zimmerman PV, Garcia-Blanco MA, Peterson B.

Cancer Detect Prev. 1998;22(1):14-9.

PMID:
9466044
18.

Smoking, gender, and survival association with allele loss for the LOH11B lung cancer region on chromosome 11.

Schreiber G, Fong KM, Peterson B, Johnson BE, O'Briant KC, Bepler G.

Cancer Epidemiol Biomarkers Prev. 1997 May;6(5):315-9.

19.
20.

Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action.

Lidor YJ, O'Briant KC, Xu FJ, Hamilton TC, Ozols RF, Bast RC Jr.

J Clin Invest. 1993 Nov;92(5):2440-7.

21.

The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines.

Rodríguez GC, Boente MP, Berchuck A, Whitaker RS, O'Briant KC, Xu F, Bast RC Jr.

Am J Obstet Gynecol. 1993 Jan;168(1 Pt 1):228-32.

PMID:
8420332

Supplemental Content

Loading ...
Support Center